1. Endo thinks it has the financial flexibility to weather the storm of opioid settlements — Takeda acquires celiac-focused PvP Biologics — Iovance jumps on buyout rumors — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

SAREPTA Therpeutics- BUYOUT setting up

Discussion in 'Industry Rumors' started by anonymous, Mar 23, 2016 at 11:20 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    SAREPTA Therpeutics- BUYOUT $40-$50/share ahead of FDA approval
     

  2. anonymous

    anonymous Guest

    Given the industry and market demand even that would be significantly low. Hope they don't and let them reach their ways on own, could see $50-70 by end of year easily
     
  3. anonymous

    anonymous Guest

    Bout time
     
  4. anonymous

    anonymous Guest

    Who
     
  5. anonymous

    anonymous Guest

    Big Pharma, dat who
     
  6. anonymous

    anonymous Guest

    Lmao
     
  7. anonymous

    anonymous Guest

    FDA approval ahead
     
  8. anonymous

    anonymous Guest

    $50 targets
     
  9. anonymous

    anonymous Guest

    First safe and efficient DMD drug. Sarepta Therapeutics
     
  10. anonymous

    anonymous Guest

    Try $80-120
     
  11. anonymous

    anonymous Guest

    What a month end it'll